FLZ demonstrates its efficacy in rotenone-induced PD mice by rejuvenating the gut microbiome, alleviating intestinal dysfunction, and curtailing inflammation and permeability through the TLR4/MyD88/NF-κB pathway. This evidence concerns the gene TLR4 and Parkinson disease.